Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pasithea TherapeuticsKTTA -3.89%29 3-Year ROIIC % is 213.31 as of Dec. 2025, which is 322% above its 10-year median of 50.51. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,322 Biotechnology companies, Pasithea Therapeutics ranks better than 84.72% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Pasithea Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 213.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pasithea Therapeutics's 3-Year ROIIC % or its related term are showing as below:
KTTA's 3-Year ROIIC % is ranked better than 84.72% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs KTTA: 213.31
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Pasithea Therapeutics 3-Year ROIIC % Related Terms
Pasithea Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Pasithea Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KTTA vs CELU, GRTX, BCDA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Pasithea Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's 3-Year ROIIC % falls into.
Pasithea Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -20.857 (Dec. 2025) - -12.589 (Dec. 2022) )
/
( 7.624 (Dec. 2025) - 11.5 (Dec. 2022) )
=
-8.268
/
-3.876
=
213.31%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pasithea Therapeutics (KTTA) has a 3-Year ROIIC % of 213.31 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pasithea Therapeutics and its competitors. This is 322% above median its historical median of 50.51. According to the industry distribution chart, Pasithea Therapeutics ranks #202 out of 1322 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Pasithea Therapeutics' 3-Year ROIIC % too high?
Pasithea Therapeutics' current 3-Year ROIIC % of 213.31 is 322% above median its 10-year median of 50.51. Based on the distribution chart, Pasithea Therapeutics ranks #202 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' 3-Year ROIIC % compare to CELU and GRTX?
According to the Biotechnology industry distribution chart, Pasithea Therapeutics ranks #202 out of 1322 companies for 3-Year ROIIC %. This places Pasithea Therapeutics in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pasithea Therapeutics and its competitors. Pasithea Therapeutics's current 3-Year ROIIC % is 213.31, which is 322% above median its own 10-year median of 50.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current 3-Year ROIIC % of 213.31. The current 3-Year ROIIC % is 213.31, which is 322% above median its 10-year median of 50.51. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current 3-Year ROIIC % is 213.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score
Get the complete analysis for KTTA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KTTA has been successfully added to your 
